Anti-tumor effect of galectin 9 in hepatocell carcinoma:Basic study
Project/Area Number |
25460998
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Gastroenterology
|
Research Institution | Kagawa University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
TANI Joji 香川大学, 医学部, 助教 (00596075)
HIMOTO Takashi 香川県立保健医療大学, 保健医療学部, 教授 (20325343)
MIYOSHI Hisaaki 香川大学, 医学部附属病院, 助教 (40592316)
HIRASHIMA Mitsuomi 香川大学, 医学部, 研究員 (70109700)
YONEYAMA Hirohito 香川大学, 医学部附属病院, 助教 (80294750)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Keywords | Hepatocellular carcinoma / Gal-9 / microRNA / Cancer / 肝細胞癌 / 膵癌 / 胆のう癌 / 胃癌 / マイクロRNA / アポトーシス / 細胞周期 / 細胞がん / マイクロRNA / 肝癌 / ガレクチン9 |
Outline of Final Research Achievements |
Anti-tumor effects of galectin-9 was detected in hepatocellular carcinoma cell induced the strong apoptosis through microRNA in vitro and in vivo(Int J Oncol. 2015 Jun;46(6):2419-30) In addition, the antitumor effect of galectin-9 was also detected in cholangiocarcinoma (Oncol Rep. 2015 Oct; 34 (4): 1761-70), gastric cancer (Oncol Rep. 2016 Feb; 35 (2): 851-60), gallbladder cancer(Int J Oncol. 2016 Mar; 48 (3): 1165-74).
|
Report
(4 results)
Research Products
(10 results)
-
[Journal Article] Galectin-9: An anticancer molecule for gallbladder carcinoma2016
Author(s)
Tadokoro T, Morishita A, Fujihara S, Iwama H, Niki T, Fujita K, Akashi E, Mimura S, Oura K, Sakamoto T, Nomura T, Tani J, Miyoshi H, Yoneyama H, Himoto T, Hirashima M, Masaki T
-
Journal Title
Int J Oncol
Volume: 48
Pages: 1165-1174
Related Report
Peer Reviewed
-
[Journal Article] Galectin-9 suppresses the proliferation of gastric cancer cells in vitro2016
Author(s)
Takano J, Morishita A, Fujihara S, Iwama H, Kokado F, Fujikawa K, Fujita K, Chiyo T, Tadokoro T, Sakamoto T, Nomura T, Tani J, Miyoshi H, Yoneyama H, Kobara H, Mori H, Niki T, Hirashima M, Masaki T
-
Journal Title
Oncol Rep
Volume: 35
Pages: 851-860
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest.2015
Author(s)
Kobayashi K, Morishita A, Iwama H, Fujita K, Okura R, Fujihara S, Yamashita T, Fujimori T, Kato K, Kamada H, Niki T, Hirashima M, Okano K, Suzuki Y, Masaki T.
-
Journal Title
Oncol Rep
Volume: 34
Pages: 1761-1770
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo2015
Author(s)
Fujita K, Iwama H, Sakamoto T, Okura R, Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, Nomura T, Tani J, Miyoshi H, Morishita A, Yoneyama H, Yamana Y, Himoto T, Okano K, Suzuki Y, Niki T, Hirashima M, Masaki T
-
Journal Title
Int J Oncol
Volume: 46
Pages: 2419-2430
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo.2015
Author(s)
Fujita K, Iwama H, Sakamoto T, Okura R, Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, Nomura T, Tani J, Miyoshi H, Morishita A, Yoneyama H, Yamana Y, Himoto T, Okano K, Suzuki Y, Niki T, Hirashima M, Masaki T.
-
Journal Title
Int J Oncol.
Volume: 46
Issue: 6
Pages: 2419-2430
DOI
Related Report
Peer Reviewed
-
[Journal Article] Galectin-9 prolongs the survival of septic mice by expanding Tim-3-expressing natural killer T cells and PDCA-1+ CD11c+ macrophages2013
Author(s)
Kadowaki T, Morishita A, Niki T, Hara J, Sato M, Tani J, Miyoshi H, Yoneyama H, Masaki T, Hattori T, Matsukawa A, Hirashima M.
-
Journal Title
Crit Care
Volume: 17(6)
Issue: 6
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-